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The fibrosis in chronic hepatitis shows dynamic changes during antiviral therapy (AVT). We investigated 
whether P-I-R (progressive vs. indeterminate vs. regressive) staging is predictive of hepatocellular 
carcinoma (HCC) recurrence in patients with chronic hepatitis B (CHB) taking AVT who underwent 
resection. Patients with CHB-related HCC who underwent curative resection between 2004 and 2017 
and had received ≥2 years AVT at the time of resection were eligible. Two pathologists performed 
P-I-R staging. In total, 104 patients with CHB-related HCC were enrolled. The mean age of the study 
population was 56.3 years. The mean duration of AVT at the time of resection was 62.6 months. During 
the follow-up period (mean, 45.5 months), 20 (19.2%) and 14 (13.5%) patients developed early and late 
recurrence of HCC, respectively. The cumulative incidence of late recurrence was significantly lower in 
patients with regressive patterns than in those with indeterminate and progressive patterns according 
to P-I-R staging (P = 0.015, log-rank test), although the cumulative incidence of overall recurrence 
according to P-I-R staging was similar. Hepatitis B virus DNA levels (hazard ratio [HR] = 3.200, 
P = 0.020) and the regressive P-I-R staging pattern (HR = 0.127, P = 0.047) independently predicted 
the risk of late recurrence. One-time assessment of the P-I-R staging at the time of curative resection in 
patients with CHB-related HCC receiving AVT independently predicted late HCC recurrence. Therefore, 
qualitative fibrosis assessment by P-I-R staging might be useful in predicting the outcomes of patients 
with CHB undergoing AVT.
Several staging systems, such as the Ishak, Metavir, and Batts systems, have been developed to evaluate the quan-
tity of fibrosis and have been used to assess the degree of liver fibrosis in patients with chronic viral hepatitis1–4. 
The Metavir staging system and the Batts and Ludwig visual interpretations have obvious value due to their sim-
plicity5. The Ishak staging system is beneficial because it has a greater score range, which allows more precision 
when classifying the degree of scarring5. In addition, histological subclassification of cirrhosis using the Laennec 
system can be more informative to assess the risk of developing liver-related events including hepatic decompen-
sation, hepatocellular carcinoma (HCC) and liver-related death in patients with cirrhosis6.
However, several issues have arisen regarding these semi-quantitative staging systems for liver fibrosis that 
render them less applicable in this era of using active and potent antiviral therapy (AVT) for patients with 
chronic hepatitis B (CHB). First, because these staging systems were established based on histological changes 
in untreated patients, their applicability in patients with CHB receiving AVT is not well known. Second, these 
systems do not explain the dynamic changes in the fibrotic burden after the initiation of AVT. For example, 
prolonged AVT with potent antiviral agents induces fibrosis regression in patients with CHB, whereas a small 
proportion of patients experience progression of fibrosis despite AVT7–10. Third, these staging systems rarely have 
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a role in the prediction of long-term prognosis according to the changed fibrotic burden after prolonged AVT. 
Some studies have demonstrated that changes in the fibrotic burden assessed by noninvasive surrogates, such as 
transient elastography, are significantly associated with long-term outcomes in patients with CHB11–14.
Recently, Sun et al.15 proposed a new staging system for the qualitative evaluation of changes in liver fibrosis 
based on histological results from paired biopsies performed during entecavir-based AVT, so called “Beijing clas-
sification”, enables the stratification of patients with CHB into three groups with different likelihoods of change 
in fibrotic burden: fibrosis progression, fibrosis indeterminate, and fibrosis regression (P-I-R staging)15. Although 
P-I-R staging may provide additional information regarding the potential for regression or progression of fibro-
sis16, no external validation study has been performed. In addition, because the P-I-R staging system was estab-
lished based on the results of paired biopsies, which are not feasibly performed in clinical practice, it should also 
be validated in a spot-time assessment setting to determine the clinical feasibility of its use.
Thus, we investigated whether P-I-R staging has prognostic value in predicting HCC recurrence, a solid clini-
cal endpoint for HCC, in patients undergoing curative resection for CHB-related HCC who had already received 
at least 2 years of AVT.
Subjects and Methods
Patients. Patients who underwent curative resection for CHB-related HCC between 2004 and 2017 at 
Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, were consecutively enrolled in this 
study. Surgical resection was performed by four experienced surgeons (DH Han, GH Choi, KS Kim, and JS Choi). 
Curative resection was defined as satisfaction of all of the following criteria: (1) complete resection of the tumor, 
(2) negative surgical resection margin according to histopathological examination, and (3) no evidence of resid-
ual tumor on computed tomography 1 month after surgery. Of these patients, 145 patients who had received ≥2 
years AVT at the time of resection were considered to be eligible.
The exclusion criteria were (1) no fibrosis to significant fibrosis (to enable observation of changes in degree 
of fibrosis following AVT), (2) co-infection with hepatitis C virus or HIV, (3) alcohol ingestion of ≥40 g/day 
for >5 years, (4) insufficient clinical data, and (5) viremia not controlled by AVT (HBV DNA >2,000 IU/mL) 
(Supplementary Fig. 1). CHB was defined as persistence of the serum HBV surface antigen for >6 months and 
HBV DNA positivity, determined by polymerase chain reaction assay.
The study protocol was consistent with the ethical guidelines of the 1975 Declaration of Helsinki and was 
approved by the institutional review board of Severance hospital (4-2019-0475). The need for informed consent 
was waived by the institutional review board because it was a retrospective study.
Recurrence. The first evaluation of postoperative complications and HCC recurrence was performed at 1 
month after surgery. Thereafter, imaging evaluations were performed every 2~3 months17. Dynamic computed 
tomography (CT) was the default imaging modality. However, if there were equivocal nodules or CT was not indi-
cated due to an allergic reaction or renal failure, dynamic magnetic resonance imaging was performed. The levels 
of tumor markers, including α-fetoprotein or des-γ-carboxy prothrombin, were also determined18,19.
The primary endpoint was HCC recurrence after curative resection. Recurrence was diagnosed based on the 
combined findings of clinical examinations and radiological imaging performed in accordance with the guide-
lines of the American Association for the Study of Liver Disease20 and subclassified as early (<2 years) and late 
(≥2 years) recurrence21,22. We defined overall recurrence to include early and late recurrence. Because early recur-
rence is known to be associated mostly with tumor factors23 and late recurrence is background liver pathology24, 
we selected only patients with late recurrence for further statistical analysis including univariate and multivariate 
analysis.
Pathological assessment. The degree of liver fibrosis was evaluated semi-quantitatively according to the 
Laennec system6. Fibrosis was scored as follows: 0, no fibrosis; 1, portal fibrosis; 2, periportal fibrosis; 3, sep-
tal fibrosis; and 4, cirrhosis. Cirrhosis was further classified as mild (4A), moderate (4B), or severe (4C) using 
Laennec staging system6. Activity was graded as follows: A0, none; A1, mild; A2, moderate; and A3, severe. The 
qualitative fibrosis evaluation using P-I-R staging system was performed like followings (Fig. 1). Progressive 
fibrosis (P) was defined as a case in which >50% of the fibroseptal stroma showed wide/broad loose collagen fib-
ers, a mixture of light and dark trichrome-stained fibers, moderate to marked infiltration of various inflammatory 
cells and ductular reactions. Regressive fibrosis (R) was defined as a case in which >50% of the fibroseptal stroma 
shows thin dense collagen fibers, mainly dark trichrome staining and sparse cellularity. Indeterminate fibrosis (I) 
was defined as an uncertain balance between progressive and regressive fibrosis15. According to our study design, 
fibrosis was assessed once in a single resected liver specimen per patient.
Two experienced pathologists (YN Park and K Na) who were blinded to the patients’ clinical information 
performed pathological evaluation of resected non-tumoral liver specimens. First, the interpretational reproduc-
ibility between the pathologists was assessed. Then, the two pathologists reviewed the slides with discordant P-I-R 
staging together and reached consensus, which was used for further statistical analysis.
Noninvasive assessment of liver fibrosis. The aspartate aminotransferase (AST)-to-platelet ratio index 
(APRI) and fibrosis-4 (FIB-4) score were calculated as additional noninvasive markers for the assessment of 
fibrosis25,26.
Statistical analysis. Data are expressed as the means ± standard deviations, medians (ranges), and n (%), 
as appropriate. Differences among continuous and categorical variables were examined with Student’s t-test (or 
the Mann–Whitney test, when appropriate) and the chi-squared test (or Fisher’s exact test, when appropriate). 
We examined inter- and intra-pathologist agreement rates, which were defined as the percentages of patients for 
which the same tumor number and treatment response results were obtained. The strength of concordance, based 
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on κ-values, was interpreted as follows: κ < 0.21, poor; κ = 0.21–0.40, fair; κ = 0.41–0.60, moderate; κ = 0.61–
0.80, good; and κ > 0.80, excellent.
Univariate and multivariate Cox proportional hazard regression analyses were used to estimate independent 
predictors of late recurrence. Hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) were calcu-
lated. The Kaplan-Meier method was used to examine the cumulative incidence of recurrence based on histolog-
ical fibrosis stage. All statistical analyses were performed using SPSS version 20.0 software (SPSS Inc., Armonk, 
NY, USA). A P-values < 0.05 were considered to be statistically significant.
Results
Baseline characteristics. After excluding 41 patients according to our exclusion criteria, 104 patients who 
had received ≥2 years AVT at the time of curative resection for CHB-related HCC were selected for analyses. 
The baseline characteristics of the study population at the time of curative resection are summarized in Table 1. 
The mean age was 56.3 ± 8.3 years, and males were predominant (74.0%, n = 77). Thirty-two (30.8%) patients 
had mild steatosis and two (1.9%) showed moderate steatosis. The mean FIB-4 and APRI scores were 3.39 ± 2.76 
and 1.47 ± 2.22, respectively. The mean duration of AVT was 62.6 ± 41.7 months. A total of 66 (63.5%) patients 
received high genetic barrier drug-based AVT (entecavir or tenofovir), and 24 (23.1%) patients had genotypic 
Figure 1. The qualitative fibrosis evaluation using P-I-R staging system was performed. Representative 
histopathologic features of P-I-R staging showing progressive (A), indeterminate (B), and regressive 
(C) in patients with chronic hepatitis B taking at least 2 years of antiviral therapy (Masson’s trichrome stain).
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mutations to lamivudine or adefovir. Hepatitis B e antigen (HBeAg) positivity was noted in 40 (38.5%) patients 
and the mean HBV DNA level was 1.7 log10 IU/mL.
At baseline, 27 (26.0%) patients still had a detectable HBV DNA in spite of ≥2 years AVT. Of these, an add-on 
strategy was applied for three patients according to their resistance profiles; eight patients were switched to a 
high-barrier drug. The other 16 patients continued previous antiviral drugs. All these patients achieved virologi-
cal response during the study period.
Pathological evaluation of fibrosis by P-I-R staging. P-I-R staging was evaluated in cases with at least 
focal fibrous septa formation or higher stages of fibrous scarring including Laennec stages 3 and 4 fibrosis, and 
was not feasible in those with less fibrosis (stages 1 and 2). The P-I-R staging of the two pathologists was in 
agreement in 96 (92.3%) cases, resulting in an excellent agreement rate (κ = 0.867, P < 0.001; Supplementary 
Table 1). After the two pathologists reviewed eight discordant cases together, 11 (10.6%), 46 (44.2%), and 47 
(45.2%) patients were finally allocated to the P, I, and R stages, respectively, which was used for the subsequent 
statistical analysis. P-I-R staging results were compared to quantitative fibrotic burden evaluated by Laennec stag-
ing system (Supplementary Table 2) P stage was correlated with Laennec stage 4C, whereas R stage was correlated 
with Laennec stage 4A (Pearson’s correlation coefficient = 0.895).
Associations between P-I-R stage and changes in noninvasive surrogates at the time of resec-
tion. We evaluated whether the P-I-R stage of non-tumoral liver at the time of HCC resection reflected the 
changes in noninvasive surrogates (APRI and FIB-4 score), during ≥2 years before resection (Table 2). For this 
analysis, an increase or decrease in the APRI or FIB-4 score was defined as >10% increase or decrease from the 
respective baseline.
During the ≥2-year AVT period, the APRI increased in 88 (84.6%) patients and was maintained in 16 (15.4%) 
patients. In contrast, the FIB-4 score increased in 42 (40.4%) patients, was maintained in 21 (20.2%) patients, and 
decreased in 41 (39.4%) patients. The agreement rates between P-I-R staging and these noninvasive surrogates 
were significantly low (13.5–29.8%; Table 2). The P-I-R staging showed poor correlations with changes in the 
APRI (κ = 0.015, P = 0.808) and FIB-4 score (κ = 0.034, P = 0.574), respectively.
Cumulative incidence of late HCC recurrence according to P-I-R staging. During the follow-up 
period (mean 45.5 ± 31.7 months), 34 (32.7%) patients experienced HCC recurrence (20 with early recurrence 
and 14 with late recurrence). Patients with HCC recurrence had similar baseline characteristics, compared to 
patients without any HCC recurrence except lower total bilirubin (mean 0.8 vs. 1.0 mg/dL, P = 0.042) and a 
higher proportion of HBeAg positivity (31.4% vs. 52.9%, P = 0.047) at the time of resection (Supplementary 
Table 3). The cumulative incidence of overall HCC recurrence according to P-I-R staging was similar (P = 0.239, 
Variables Values
Demographic data
Age, years 56.3 ± 8.3
Male gender 77 (74.0)
Body mass index, kg/m2 24.1 ± 2.5
Duration of AVT, months 62.6 ± 41.7
High genetic barrier drug-based AVT 66 (63.5)
Genotypic mutation 24 (23.1)
Laboratory data
Platelet count, 109/L 142.7 ± 44.3
Aspartate aminotransferase, IU/mL 62.3 ± 78.5
Alanine aminotransferase, IU/mL 58.9 ± 72.0
Total bilirubin, mg/dL 0.9 ± 0.6
Serum albumin, g/dL 4.1 ± 0.6
Prothrombin time, INR 1.0 ± 0.1
HBeAg positivity 40 (38.5)
HBV DNA, log10 IU/mL 1.7 ± 0.9
HCC stages
BCLC A/B/C 101/3/0
pTNM I/II/III/IVA 67/27/7/3
Fibrosis assessment
FIB-4 3.39 ± 2.76
APRI 1.47 ± 2.22
Table 1. Baseline characteristics at the time of curative resection of HCC (n = 104). Values are expressed as 
mean ± SD or n (%). HCC, hepatocellular carcinoma; AVT, antiviral therapy; INR, international normalized 
ratio; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; BCLC, Barcelona Clinic Liver Cancer; pTNM, 
pathological Tumor, Node, Metastasis; FIB-4, fibrosis-4; APRI, aspartate aminotransferase to platelet ratio 
index.
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log-rank test; Fig. 2A). Patients with late HCC recurrence had higher alanine aminotransferase (ALT; mean, 59.4 
vs. 33.7 IU/mL; P = 0.004) and higher HBV DNA level (mean, 2.2 vs. 1.5 log10 IU/mL; P = 0.002) levels than those 
without recurrence (Table 3). The cumulative incidence of late HCC recurrence was significantly lower in patients 
with the regressive fibrosis pattern than in those with the indeterminate and progressive fibrosis patterns of P-I-R 
staging (P = 0.015, log-rank test; Fig. 2B). The progressive group tended to have a higher risk for HCC recurrence 
than the indeterminate group (P = 0.261, log-rank test) and the combined group of patients with indeterminate 
and regressive fibrosis (P = 0.092, log-rank test).
Independent predictors of late HCC recurrence. ALT and HBV DNA levels, and regressive fibrosis 
pattern of P-I-R staging status were significant in the univariate analysis and were selected for the sequential 
multivariate analysis (Table 4). A higher HBV DNA level was associated independently with an increased risk of 
late recurrence (HR = 3.200, 95% CI = 1.202–8.518, P = 0.020), whereas the regressive fibrosis pattern of P-I-R 
staging pattern was associated independently with a reduced risk of late recurrence (HR = 0.127, 95% CI = 0.017–
0.971, P = 0.047).
Paired pathological data. Paired pathological data were available for 10 patients (Supplementary Table 4). 
During follow-up, seven (70.0%) patients showed improved in P-I-R staging (from progressive to regressive in 
three patients and from indeterminate to regressive in four patients). Six (60.0%) patients exhibited regression 
of fibrosis amount according to the Laennec system (from F4B to F4A in three patients, from F4Cto F4B in two 
Noninvasive surrogates and their 
changes
P-I-R staging
Agreement 
rate (%) κ-value
P 
value
Progressive Indeterminate Regressive
Surrogates Changes* n = 11 n = 46 n = 47
APRI
Increased (n = 88) 8 40 40
13.5 0.015 0.808Maintained (n = 16) 3 6 7
Decreased (n = 0) 0 0 0
FIB-4
Increased (n = 42) 3 21 18
29.8 0.034 0.574Maintained (n = 21) 4 8 9
Decreased (n = 41) 4 17 20
Table 2. P-I-R staging at the time of HCC resection vs. changes in noninvasive surrogate markers during 
≥2 years before resection. *Increased and decreased were defined as >10% increases and decreases from 
baseline, respectively. Maintained was defined as <10% from baseline. HCC, hepatocellular carcinoma; APRI, 
aspartate aminotransferase to platelet ratio index; FIB-4, fibrosis-4.
Figure 2. Cumulative incidence rates of HCC recurrence. (A) The cumulative incidence of overall recurrence 
did not differ according to P-I-R staging (P = 0.239, log-rank test). (B) The cumulative incidence of late 
recurrence was significantly lower in patients with the regressive pattern than in those with the indeterminate 
and progressive patterns (P = 0.015, log-rank test).
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patients, and from F4B to F3 in one patient). No case showed fibrosis progression in P-I-R staging when the 
patient had received >2 years AVT.
Discussion
Repeated biopsy to check for dynamic changes in the histological response to AVT is not always feasible in clinical 
practice. Recently, P-I-R staging, which was developed based on paired liver biopsies was reported to be useful 
to evaluate the dynamic changes in fibrosis. To improve applicability in clinical practice, one- time assessment 
of P-I-R staging needs to be validated whether it reflects progressive or regressive fibrosis changes in histological 
features after prolonged AVT. Thus, we investigated P-I-R staging in non-tumoral liver of CHB in HCC patients 
with ≥2 years AVT at the time of curative resection. One-time P-I-R assessment predicted the risk of late HCC 
recurrence (P = 0.015), and the regressive fibrosis pattern of P-I-R staging was associated independently with a 
reduced risk of late HCC recurrence (HR = 0.127).
Several studies have shown the clinical implications of histological subclassification of cirrhosis using the 
Laennec system, based on the different nodule sizes and fibrous septa thickness6,19,27. We confirmed previously 
that stage 4A is associated with better prognosis than are stage 4B and 4C in terms of the reduced risk of devel-
oping decompensation, HCC, or mortality6. In contrast to quantitative assessment of fibrosis using the Laennec 
system, P-I-R staging, qualitative fibrosis evaluation focuses on dynamic changes in the fibrotic burden dur-
ing prolonged AVT. Interestingly, progressive fibrosis pattern was correlated with Laennec stage 4C, whereas 
regressive fibrosis pattern was correlated with Laennec stage 4A. In addition, among eight patients showing the 
regressive pattern at follow-up paired histological assessment, six (60.0%) exhibited regression of fibrosis amount 
according to the Laennec system. These results suggest that the performance of qualitative fibrosis assessment 
of P-I-R staging system in addition to quantitative fibrosis evaluation by Laennec staging system would be help-
ful for comprehensive interpretation of dynamic fibrosis status during AVT (Supplementary Table 2). In our 
cohort, the presence of steatosis did not affect the risk of HCC recurrence (p = 0.727 by log-rank test). This can 
be explained in part by that all included patients already had advanced fibrosis, which might offset the effects of 
the steatosis on HCC recurrence.
Our study has several strengths. First, we used late HCC recurrence as a solid clinical endpoint for longitu-
dinal validation. In contrast, previous studies have involved qualitative assessment of changes in fibrosis at 78 
weeks after AVT, but no investigation of the association with prognosis and disease progression in patients with 
Variables
No recurrence Late HCC recurrence
P valuen = 59 (80.8%) n = 14 (19.2%)
Demographic data
Age, years 56.8 ± 52.8 52.8 ± 9.4 0.108
Male gender 43 (72.9) 11 (78.6) 0.475
Body mass index, kg/m2 23.8 ± 2.5 23.5 ± 2.0 0.671
Duration of AVT, 
months 69.6 ± 46.4 47.1 ± 20.9 0.082
High genetic barrier 
drug-based AVT 33 (55.9) 6 (42.9) 0.279
Genotypic mutation 18 (30.5) 5 (35.7) 0.467
Laboratory data
Platelet count, 109/L 144.4 ± 46.4 149.2 ± 46.2 0.730
Aspartate 
aminotransferase, IU/
mL
34.6 ± 23.8 50.4 ± 53.2 0.095
Alanine 
aminotransferase, IU/
mL
33.7 ± 20.9 59.4 ± 51.1 0.004
Total bilirubin, mg/dL 0.9 ± 0.4 0.7 ± 0.3 0.217
Serum albumin, g/dL 4.3 ± 0.5 4.4 ± 0.3 0.344
Prothrombin time, INR 1.0 ± 0.2 1.0 ± 0.1 0.890
HBeAg positivity 22 (37.3) 7 (50.0) 0.298
HBV DNA, log10 IU/mL 1.5 ± 0.5 2.2 ± 1.3 0.002
P/I/R stages, n (%)
2 (3.4)/28 
(47.5)/29 
(49.2)
4 (28.6)/7 (50.0)/3 
(21.4) 0.005
Fibrosis assessment
FIB-4 2.74 ± 2.03 2.42 ± 1.93 0.594
APRI 0.81 ± 0.61 1.07 ± 1.30 0.263
Table 3. Comparison of patients with and without late HCC recurrence*. Values are expressed as mean ± SD 
or n (%). *Patients who died or who were followed-up for less than 2 years were excluded. HCC, hepatocellular 
carcinoma; AVT, antiviral therapy; INR, international normalized ratio; HBeAg, hepatitis B e antigen; HBV, 
hepatitis B virus; FIB-4, fibrosis-4; APRI, aspartate aminotransferase to platelet ratio index.
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CHB15,28. Given the relevance of the association between the fibrotic burden and risk of HCC recurrence29, exam-
ination of the fitness of any fibrosis stratification through the longitudinal analysis of associations is appropriate. 
Indeed, our previous study confirmed the fitness of Laennec staging system, which subclassifies histological cir-
rhosis, revealing differences in the risk of HCC development according to the quantitatively subclassified fibrotic 
burden6. In this study, the qualitative fibrosis evaluation of P-I-R staging was found to predict the late HCC 
recurrence.
Second, P-I-R staging was conducted with resected specimens in our study. This approach may have almost 
completely avoided the conventional pitfalls of histological interpretation based on percutaneous liver biopsy and 
ensured the high reliability of P-I-R staging. In contrast, other studies have been based on P-I-R staging using 
needle biopsy specimens15, which might be vulnerable to a high rate of interpretational variability and sampling 
error30. This issue might explain the higher inter-pathologist reproducibility (κ = 0.867), even with single-time 
assessment, compared with that reported by Sun et al.15 for paired biopsy samples (κ = 0.71).
Third, because most patients experience fibrosis regression after appropriate AVT, P-I-R staging, qualitative 
evaluation of fibrosis is considered to be more clinically relevant in the current era of active AVT compared to 
classical staging systems with quantitative fibrosis evaluation, which were developed based on histological changes 
in untreated patients with CHB16,31. Our study included a homogenous group of patients with CHB-related HCC, 
who received ≥2 years AVT at the time of curative resection, but they received a wide spectrum of antiviral agents 
at the time of HCC resection similar to the actual clinical situation, and not including only entecavir, as in a 
previous study28. The inclusion of low-genetic-barrier drugs might not have influenced our final results, as appro-
priate rescue therapy for the mutant strain does not affect in the risk of HCC development according to the use of 
low- or high-genetic-barrier drugs8. Furthermore, our follow-up period after curative resection of HCC was long 
(median 68.1 months), which enabled us to investigate the association between P-I-R staging and the long-term 
risk of HCC recurrence. Despite exhibiting the regressive fibrosis pattern, three (6.4%, 3/47) patients developed 
late HCC recurrence. Taken together, these findings indicate that HBV remains still the important cause of HCC 
development, especially in the presence of advanced fibrosis or cirrhosis32.
We are aware of several issues with our study that remains unresolved. First, as a retrospective study, it is not 
free from potential selection bias. Indeed, only patients with preserved liver function who underwent curative 
HCC resection were included. In addition, because we evaluated regression and progression of fibrosis using 
P-I-R staging, the patients with mild fibrosis showing no histologically fibrotic septa cannot be evaluated. Second, 
based on reliable histological interpretation using resected specimens, we showed high inter-pathologist repro-
ducibility of P-I-R stage even with single assessments. However, the small number of cases (n = 104) who under-
went resection after an adequate AVT period of >2 years is a main limitation in our study. The paired biopsy data 
were taken from an extremely small sample (n = 10), and confirmation of the exact correlation between P-I-R 
staging and the risk of HCC recurrence was difficult. Third, the mass effect of HCC on the non-neoplastic liver 
could not be ruled out completely because fibrosis is usually more severe in the liver tissue adjacent to HCC than 
Variables
Univariate Multivariate
P value HR (95% CI) P value HR (95% CI)
Age, years 0.113 0.942 (0.876–1.014)
Male gender 0.664 1.364 (0.337–5.531)
Duration of AVT, months 0.099 0.982 (0.960–1.003)
Platelet count, 109/L 0.725 1.002 (0.990–1.015)
Alanine aminotransferase, IU/mL 0.018 1.023 (1.004–1.042) 0.131 1.020 (0.994–1.046)
HBeAg positivity 0.411 1.636 (0.506–5.295)
HBV DNA, log10 IU/mL 0.018 2.682 (1.188–6.054) 0.020 3.200 (1.202–8.518)
Alpha fetoprotein, ng/mL 0.942 1.000 (0.994–1.006)
Fibrosis assessment
FIB-4 0.592 0.904 (0.625–1.307)
APRI 0.285 1.414 (0.749–2.670)
F4B, 4 C (vs. F4A, F2-3) 0.057 3.257 (0.965~10.991)
F4 fibrosis (vs. F2-3) 0.620 1.382 (0.386–4.950)
P-I-R staging
Regressive (vs. 
indeterminate + progressive) 0.009 0.088 (0.014–0.544) 0.047 0.127 (0.017–0.971)
Tumor size, cm 0.986 0.993 (0.460–2.143)
Tumor number 0.911 0.895 (0.128–6.235)
Edmonson grade 3 (vs. grade 1–2) 0.080 0.292 (0.074–1.158)
TNM stage II + III (vs. I) 0.253 0.446 (0.112–1.778)
Table 4. Independent predictors of late HCC recurrence*. *A total of 73 (14 patients with late recurrence and 
59 patients were followed for more than 2 years without recurrence) were included. HR, hazard ratio; 95% CI, 
95% confidence interval; HCC, hepatocellular carcinoma; AVT, antiviral therapy; HBeAg, hepatitis B e antigen; 
HBV, hepatitis B virus; FIB-4, fibrosis-4; APRI, aspartate aminotransferase to platelet ratio index; TNM, Tumor-
Node-Metastasis.
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in background liver tissue far from the mass33. As the size and number of HCC nodules that were eligible for cura-
tive resection were small, we believe that the tumor effects on fibrosis with respect to surrounding liver histology 
were likely negligible. In addition, we cannot exclude the possibility that participants who underwent resection 
due to HCC had greater fibrotic burdens than do actual CHB patients without HCC. Fourth, the cumulative 
recurrence rate was not different according to Union for International Cancer Control (UICC) stage (P = 0.956, 
log-rank test). This result might be explained in part by that most patients in our cohort had early-stage HCC. 
Lastly, there was a discrepancy between the changes in APRI and FIB-4 scores. Here, we defined that increased 
and decreased were defined as >10% increase and decrease from baseline, respectively. Therefore, the changes of 
these noninvasive fibrosis markers may not be accurately reflected the pathological changes. In addition, weak 
correlations between P-I-R staining and non-invasive markers might be explained, in part, by APRI and FIB-4 
scores’ being unsatisfactory for assessing fibrotic burden according to the Ishak stage34.
In conclusion, one-time assessment of P-I-R staging in patients with CHB-related HCC receiving AVT inde-
pendently predicted the late recurrence of HCC. Therefore, qualitative fibrosis assessment by P-I-R staging in 
addition to semiquantitative fibrosis evaluation using a previously developed staging system is considered to 
provide more comprehensive information for the dynamics of fibrosis status and prediction of the outcomes in 
patients with chronic hepatitis undergoing AVT.
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